News

Quote


















Don't Come Knockin' On My Door

The pharma industry doesn’t need more stats to tell it that knocking on doors doesn’t work any more, but some new figures blast that cold reality. (A comprehensive review of what needs fixing in pharma's commercial model is in the December IN VIVO. Our take on Merck's stab at reinvigorating its commercial presence is here.)

The latest data comes from California-based market research firm SK&A, which found the percentage of doctors who require reps to make appointments for visits rose 22 percent between June and December 2008 from 31.4 to 38.5 percent (of doctors who see reps). The number of physicians who won’t even see sales reps at all rose from 22.3 percent to 23.6 percent (of all surveyed).

Put another way: about 40 percent of general practitioners--that is, the ones who see reps at all--now require appointments, up from 33 percent six months ago. The trend rose for specialists too-from 28.3 percent in June to 36.6 percent in December. Every kind of practice and specialty is getting tougher, although specialty physicians are more likely to completely bar reps than GPs. Among the toughest to get to: pathologists, diagnostic radiologists, and neuroradiologists. No specialty stood out as particularly friendly, although dermatologists, allergists, and diabetes specialists were least likely to impose total lock outs.

The survey didn’t ask why doctors are increasing their restrictions, but SK&A researchers do speculate. Doctors are busier, under pressure to see more patients – and, affiliated with large organizations that increasingly institute system-wide rules. Not surprisingly, then, health systems are the most restrictive: more than half require appointments and 35 percent forbid rep access altogether. Of free-standing medical practices, those owned by hospitals stand out: 44.6 percent of those that see reps require appointments, while 31 percent keep their doors shut.

Lest anyone dismiss this data as fly-by-night, SK&A says it conducted telephone interviews with 227,000 medical practices representing 640,000 doctors—that’s nearly all of the active practicing physicians in the U.S. The response rate was 94 percent.

There is a silver lining. Some 76.4 percent of those surveyed, including the group that requires appointments, still see reps. And those appointments could be more productive. The survey didn’t measure quality of interaction, but SK&A CEO Dave Escalante points out that doctors who agree to visits by appointment may be opting for higher quality time with their rep, which scheduling in advance could provide. SK&A, however, didn’t look at the reasons for the new barriers to access or the quality of doctor-rep relations, although multitudes of others have.

The message? Well it hardly needs to be repeated, but hard numbers always resonate: large armies of sales forces are a model that just won’t work anymore.--Wendy Diller
 






Uroplasty Reports First Fiscal Quarter Results
4:05 pm ET 08/03/2009 - PR Newswire

MINNEAPOLIS, Aug. 3 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the first fiscal quarter ended June 30, 2009.

"Our team is successfully executing the strategy we communicated at the beginning of the fiscal year of growing U.S. Macroplastique sales and accumulating the clinical data for seeking a unique CPT code for Urgent PC((R)) treatments," said David Kaysen, President & CEO. "While our fiscal first quarter financial performance is below year-ago results, we are encouraged by our U.S. Macroplastique sales that have doubled from last year's fiscal first quarter. Our European Macroplastique sales were impacted by a recently resolved distributor over-stock issue, change in a distributor in a key market, and a new competitive product entry we noted earlier this year. At the same time, we have been managing expenses to conserve cash while investing in R&D, namely the SUmiT clinical study."

Fiscal First Quarter Results for the Period Ended June 30, 2009

Net sales for the three months ended June 30, 2009 were $2.8 million versus $4.5 million for the same period a year ago.

Sales to customers in the U.S. during the three months ended June 30, 2009 totaled $1.5 million, representing a 34% decrease, over net sales of $2.2 million for the three months ended June 30, 2008. Sales of our Urgent PC of $1.0 million declined from $2.0 million in the year-ago quarter. The trend in decline of our Urgent PC sales over corresponding year-ago periods began in the second half of fiscal 2009 due to reimbursement related issues. Partially offsetting this decline was an increase in Macroplastique sales to $0.4 million from $0.2 million in the year-ago quarter. Sales of Macroplastique product have steadily increased because of increased sales and marketing focus.

Sales to customers outside of the U.S. for the three months ended June 30, 2009 were $1.4 million, down 41% from $2.3 million in the year-ago period. Excluding the translation impact of fluctuations in foreign currency exchange rates, sales to customers outside of the U.S. declined approximately 31%. The sales decrease is mainly attributed to the strengthening of the U.S. dollar against the Euro and the British pound, increased competition from a newly-introduced product against the Macroplastique product, inventory buildup in the previous quarters at one of the European distributors, a change in distributor in another European country and discontinuation of our I-Stop urethral sling product in the United Kingdom.

Net loss for the first fiscal quarter ended June 30, 2009 was $1.4 million, or $0.09 per diluted share, versus a net loss of $0.4 million, or $0.03 per diluted share for the first quarter of last year.

At June 30, 2009, cash and cash equivalents, and short-term investments were $6.3 million compared with $7.8 million at March 31, 2009 and $8.6 million at December 31, 2008.


"Our first quarter Urgent PC results reflect the continued challenging environment for our Urgent PC system due to the ongoing reimbursement uncertainties in the U.S. market," continued Mr. Kaysen. "As we have noted in the past, we expect these uncertainties to continue until after the Urgent PC is assigned a new listed CPT code by the American Medical Association (AMA) and payors create coverage policies that provide adequate reimbursement. A major part of our strategy to expand and support third-party reimbursement coverage of Urgent PC treatment is the SUmiT clinical study, which we announced in October 2008. The study is designed to directly compare the effectiveness of Urgent PC treatment to a non-active sham treatment with 219 enrolled subjects at 22 urology and urogynecology centers across the United States. The study is evaluating reductions in urinary urgency, urge incontinence, and frequency of urinary voids, as well as patient quality of life measures. Currently, study data are being analyzed and a manuscript for publication is under development. We expect the manuscript will be submitted for publication by the early fall, slightly ahead of our original plan," Mr. Kaysen added.


"Macroplastique continues to build sales momentum in the U.S.," said Mr. Kaysen. "In the U.S., we are benefiting from our sales and marketing strategy that highlights the clinical and competitive advantages of Macroplastique and the sales force is doing a good job of adding customers. At the same time, our European sales momentum with Macroplastique has been challenged by the launch of a competitive product, the strengthening of the U.S. dollar against the Euro and the British pound, and, as previously noted, distributor issues in a few key markets. We have now resolved the distributor issues, expect the competitive product impact on sales to stabilize and, overall, we remain optimistic the Macroplastique line will continue to be viewed as the 'gold standard' for bulking agents," said Mr. Kaysen.


"Looking ahead, we expect sales of our Macroplastique product in the U.S. to continue to grow during the remainder of the year as we expect to benefit from our increased sales and marketing effort," continued Mr. Kaysen. "However, we do not expect that we will be able to return to significant sales growth or return to the historic sales level of Urgent PC in the U.S. until a new listed CPT code is assigned and payors create coverage policies that provide adequate reimbursement.


"For the past three quarters we have been implementing a comprehensive program designed to educate Medicare carriers and private payer medical directors around the country about the benefits and clinical study results of Urgent PC. During the quarter no Medicare or private payer carrier changed or eliminated Urgent PC coverage. We continue to generate additional peer-reviewed publications on percutaneous tibial nerve stimulation (PTNS) treatments, and, to date, 12 articles have been published in U.S. peer-reviewed medical and nursing journals. And, we understand that the 12-week results of our earlier OrBIT clinical study have been accepted for publication in the September issue of the Journal of Urology, and the 12-month follow-up results from the same study have been accepted for publication in the January 2010 issue of the same journal. We are hopeful these publications will lead the medical directors to reaffirm or reinstate reimbursement, as well as aid us in our application to the AMA for the CPT code. Our overall goal remains to receive a listed CPT code that will encourage broader use of our Urgent PC. We are confident that we are continuing to move toward that objective," Mr. Kaysen concluded.


Conference Call

Uroplasty will host an audio conference call today at 3:30 pm Central, 4:30 pm Eastern, to review the financial results for the first fiscal quarter of 2010. David Kaysen, President and Chief Executive Officer and Medi Jiwani, Vice President, Chief Financial Officer and Treasurer will host the call. Individuals wishing to participate in the conference call should dial 877-941-1466 (domestic) or 480-629-9644 (international). An audio replay will be available for 30 days following the call at 800-406-7325 (domestic) or 303-590-3030 (international), with the passcode 4119644#.
 






Conference call recap;

Macroplastique sales have doubled. Ouside US, Macroplastique lower sales due to increased dollar value, distributor issues and new competitor.

Early fall submission for recent Urgent PC study.

I-stop discontinued in European market.

Relatively few private payers are still reimbursing. No recent Medicare loses.

Orbit 12 week study to be published in September 2009.
Orbit 12 month study to be published in January 2010.

Expects Urgent PC to be lower next year.
Urgent PC special code expected in Jan. 2011.

Outside US, Macroplastique competitor launched. Normal lower of numbers during competitor launched and expected to bounce back.
 






Investor Charlie question;

Will private payors start reimbursing in June 2010 if the AMA grants code in Feb. 2010?
AMA information made public in July 2010. Medicare payors will wait until Jan. 2011. Private payors may make decisions prior to Jan. 2011.

What was the Urgent PC coverage spilt between Medicare vs. Private payor?
Medicare was the higher payor.

New outside bulking competitor?
Danish based company. 4 -6 years before US approval. Introduced in Europe in the main centers and key opinion leaders. Physicians given free product for 4 - 8 months. Macroplastique is the gold standard.

What happened with the outside US competitor?
France and Italy.
One was in an overstock situation due to a computer glich.
Direct Netherland rep. is helping distributor work through the issues.
Second distributor changed ownership, changed focus, reps. were dumped, and had a fire sale on product.
New distributor has hired dumped reps from old distributor.
Turnover in direct UK sales reps.

Question from Joe;
Why payors may not pay?

Meeting with medical directors and present new peer-reviewed data.

When you receive the code, what types of sales growth would be expected?
Gear up to relaunched Urgent PC in 2011.

Question from Kevin;
How many physicians? Breakdown the 41%.
1/4 foreign currency, 1/3 two distibutor issues, competitor hard to breakout.

Number of active UPC accounts 221 last quarter 255.
 






I am SO happy that OrBIT is finally going to be published. I can't wait to tell all of your physicians that PTNS is compatable to Detrol LA. For a few years your clients have been using the incorrect code, the test cost, and being OVER reimbursed my Medicare. How do you think your clients will feel now that you have proven that PTNS works AS WELL AS DETROL LA.
What do you think your chances are now with your own code? Why bother? The reimbursement amount is not going to be anywheres near what physicians get reimbursed for doing Interstim test leads in their offices. The physician can prescirbe Detrol LA and not worry about losing money on Urgent PC, no forms to fill out, no denial process, no taking up a room for 1 hour and not being reimbursed for it. Detrol LA is covered by all managed care companies and the generic Detrol makes it even cheaper. The patients will receive free samples and see results (if any) before paying one red cent. Does PTNS work that way? Nope.
After the patient has failed several OAb drugs, the physician can perform an Interstim test lead procedure, the patient will check for results and then receive an Interstim, if applicable.

The physician will NOT have any unreimbursed costs. Can you say that about PTNS? How many physicians are paying back insurances companies for PTNS? How many accounts are stuck with your stimulator and leads that they are not ALLOWED to return?

You guys just keep digging a deeper and deeper hole.
Does anyone there have ANY experience with reimbursement, marketing, and management? Or do you just fly by the seat of your pants?
 












Anonymous said:
http://emkinetics.com/

New competitor.
Click to expand...

Study Type: Interventional
Study Design: Treatment, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Official Title: Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder


Further study details as provided by EMKinetics, Inc:


Primary Outcome Measures:
•Improved urinary frequency and urgency after 12 weeks of treatment. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]


Secondary Outcome Measures:
•To estimate the extent to which the device will decrease the number of episodes of involuntary urine loss due to frequency/urgency in comparison to historical controls [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

•To evaluate the potential of the device for improving patient quality of life as measured by a clinically validated scale, such as the Incontinence Quality of Life Instrument (I-QOL) or equivalent [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

•To periodically employ a micturition diary to record variables such as day/night urgency/frequency episodes, number of voids per day, severity of leaks, number of absorbent products used per day, etc [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]


Enrollment: 4
Study Start Date: December 2008
Estimated Study Completion Date: April 2010
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)

Intervention Details:
Device: MagPro R30
Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil.

The figure eight coil is placed directly over the posterior tibial nerve and the MagPro R30 will be activated.

The coil will stimulate the posterior tibial nerve at 20 pulses per second for a 30 minute session.

Detailed Description:
Twenty to Forty patients with documented overactive bladder will receive 30 minutes of treatment one day a week for 12 weeks. Treatment will consist of stimulating the posterior tibial nerve in the area of the ankle with a pulsed electromagnetic field. Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil, and a surface electrode placed over the afferent pathway of the sacral nerve.

The specific aim is improved urinary frequency and urgency after 12 weeks of treatment.

Secondary goals.

•To estimate the extent to which the device will decrease the number of episodes of involuntary urine loss due to frequency/urgency in comparison to historical controls.
•To evaluate the potential of the device for improving patient quality of life as measured by a clinically validated scale, such as the Incontinence Quality of Life Instrument (I-QOL) or equivalent
•To periodically employ a micturition diary to record variables such as day/night urgency/frequency episodes, number of voids per day, severity of leaks, number of absorbent products used per day, etc.
Eligibility


Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria
Inclusion Criteria:

•The patient is > 18 years old.
•The patient has ≥ 6 month history of documented overactive bladder.
•The patient has failed other conventional therapy (i.e.- Kegel exercises, biofeedback methodology, etc.).
•The patient is free of mechanical urethral obstruction as documented by cystoscopy or pressure flow criteria.
•The patient demonstrates an understanding of neuromodulation therapy, its benefits, and its potential risks.
•The patient is willing and able to keep accurate records of their voiding on the provided voiding diaries.
•The patient is willing and able to comply with the Study Protocol.
•The patient agrees to and is capable of answering a quality of life questionnaire.
•The patient has normal functioning of the upper urinary tract.
•The patient has an intact peripheral neurosensory system.
•If the patient is/was on pharmacologic treatment for urgency/frequency syndrome, a 10-day washout period prior to treatment must be completed.
•The patient has sufficient outlet resistance at the urinary sphincter (i.e.- the patient does not have intrinsic sphincter deficiency).
Exclusion Criteria:

•The patient is pregnant or intends to become pregnant during the course of the study. (Patients becoming pregnant during the course of the study will immediately be terminated from the study.) Warning: The effects of neuromodulation on a developing fetus are unknown
•The patient has an active urinary tract infection.
•The patient has abnormal cystoscopy, which is concerning for or indicative of malignancy.
•The patient has a urinary fistula.
•The patient has a bladder stone.
•The patient has had ankle injury or surgery which results inability to stimulate the tibial nerve or discomfort in using the foot cradle
•The patient has metal implant from surgery or a metallic foreign body in either leg below (distal to) the knee.
•The patient has cochlear implants.
•The patient has a hyperreflexic neurogenic bladder or urodynamically proven instability secondary to a known neurourologic cause (i.e.- stroke, Parkinson's, Multiple Sclerosis).
•The patient has had four or more urinary tract infections in the past year.
•The patient has a chronic disease or diminished mental capacity that, in the Principal Investigator's judgement, would impair their ability to successfully understand and comply with the protocol.
•The patient has a history of gross hematuria or glycosuria within the last year.
•The patient has chronic constipation (less than two (2) bowel movements per week).
•The patient has significant pathology that would compromise sphincter competency.
•The patient has uncontrolled diabetes.
•The patient has diagnosed peripheral neuropathy such as diabetes with peripheral nerve involvement.
•The patient has concomitant medical conditions that would limit the success of the procedure or confound study results, including but not limited to patients with nerve damage, pacemakers or implantable defibrillators.
•The patient is unable or unwilling to sign informed consent.
•The patient is on pharmacologic treatment that could affect bladder function.
•The patient has known moderate to severe ureteral reflux or hydronephrosis.
•The patient has severe urethral stricture(s).
Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00805779

Locations
United States, California
UCSF Urology Faculty Practice
San Francisco, California, United States, 94122
Sponsors and Collaborators
EMKinetics, Inc
Investigators
Principal Investigator: Donna Y Deng, MD UCSF Department of Urology

More Information

No publications provided

Responsible Party: UCSF ( Donna Deng, MD/Assistant Professor )
Study ID Numbers: EMK1208
Study First Received: December 8, 2008
Last Updated: June 2, 2009
ClinicalTrials.gov Identifier: NCT00805779 History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by EMKinetics, Inc:
Overactive Bladder
Overactive Urinary Bladder
Bladder, Overactive
Overactive Detrusor
Detrusor, Overactive
Overactive Detrusor Function
Detrusor Function, Overactive



Study placed in the following topic categories:
Signs and Symptoms
Urinary Bladder, Overactive
Cystocele
Urologic Diseases
Urinary Bladder Diseases



Additional relevant MeSH terms:
Signs and Symptoms
Urological Manifestations
Urinary Bladder, Overactive
Urologic Diseases
Urinary Bladder Diseases



ClinicalTrials.gov processed this record on September 04, 2009
 






Anonymous said:
http://emkinetics.com/

New competitor.
Click to expand...

Detailed Description:
Twenty to Forty patients with documented overactive bladder will receive 30 minutes of treatment one day a week for 12 weeks. Treatment will consist of stimulating the posterior tibial nerve in the area of the ankle with a pulsed electromagnetic field. Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil, and a surface electrode placed over the afferent pathway of the sacral nerve.

The specific aim is improved urinary frequency and urgency after 12 weeks of treatment.
//////////////
The are using our protocol.
 






Anonymous said:
Detailed Description:
Twenty to Forty patients with documented overactive bladder will receive 30 minutes of treatment one day a week for 12 weeks. Treatment will consist of stimulating the posterior tibial nerve in the area of the ankle with a pulsed electromagnetic field. Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil, and a surface electrode placed over the afferent pathway of the sacral nerve.

The specific aim is improved urinary frequency and urgency after 12 weeks of treatment.
//////////////
The are using our protocol.
Click to expand...

http://www.alpinebiomed.com/MagPro.aspx
 






Johnson & Johnson: Senate health plan's proposed tax on medical device makers could cost jobs

By Linda A. Johnson, AP Business Writer
On 4:14 pm EDT, Tuesday October 13, 2009

TRENTON, N.J. (AP) -- Johnson & Johnson executives said Tuesday a proposed tax on medical device makers, part of the health care reform package moving in the Senate, is too high and could cost jobs in the industry.
"We think that the $4 billion tax that they're referring to is unreasonable," J&J Chief Financial Officer Dominic Caruso told The Associated Press in an interview. "We believe it's at least twice what it ought to be."

Caruso spoke after New Brunswick, N.J.-based J&J reported its third-quarter earnings, which included a tiny profit increase and sales declines in every division except medical devices, due to the effects of generic competition and the recession.

Johnson & Johnson is the world's top-selling maker of medical devices and diagnostic products, with items ranging from surgical implements and cardiac stents to Acuvue contact lenses and hospital blood analysis machines.

Caruso told analysts during a conference call that the proposed $4 billion-a-year tax would amount to about 3 percent of total medical device industry revenues, now approximately $125 billion a year. He said that could increase the typical tax rate for companies in the industry by about 11 percent.

Alex Gorsky, head of medical devices and diagnostics at J&J, said such a high tax could become onerous.

"We're hopeful that we can get legislation through that's fair but also permits an environment of innovation," Gorsky said.

Caruso said company executives, along with the industry trade group AdvaMed, continue to tell the Obama administration and members of Congress why they believe such a high tax would be unfair. He said it "might have the unintended consequence of stifling innovation" and eventually reduce the number of U.S. jobs in the industry.
---------
This would hurt us.
 






AstraZeneca Offers Buyouts To Its Entire Sales Force

By Ed Silverman // October 19th, 2009 // 7:22 am

The big drugmaker faces the same problems as the rest of the industry and so, last week, asked its entire sales force - which numbers between 5,000 and 6,000 in the U.S. - to decide whether to accept a package. However, AstraZeneca prefers to avoid the term buyout and instead instructed its reps to ’self identify’ their interest in walking out the door.

At the same time, the drugmaker is merging portions of its various sales teams - the CNS division with with the Hospital group and the Respiratory division with Medical Care. An AstraZeneca spokesman declined to discuss specifics - such as the total number of reps the drugmaker would like to shed - but did provide this statement:

“AstraZeneca is making changes to our sales force, which will be managed first by looking at vacancies and offering field sales employees the opportunity to self-identify whether they are interested in leaving the company. We will know the full scope of the changes in the coming weeks.”

Zacks Investment Research recently predicted AstraZeneca will lose $11.1 billion in patented-protected revenue by the end of 2012. One of the biggest sellers to eventually face lower-cost generics will be Seroquel XR, the antipsychotic, which generated about $4.5 billion in revenue last year.
---
Be grateful to have a job.
 






C.R. Bard Surpasses Zacks Estimate
By Zacks Equity Research
C.R. Bard, Inc. yesterday reported strong third quarter fiscal 2009 results after the market close. Earnings per share were $1.31, surpassing the Zacks Consensus Estimate of $1.27 and the year-ago earnings of $1.09.

Sales

Net sales in the quarter increased 3% year over year to $637.0 million. Excluding an unfavorable foreign currency translation (FX), net sales increased 6% year over year. On a geographic basis, U.S. sales contributed approximately 69.5% of total sales and increased 6% year over year. International sales declined 1% year over year.

Growth was witnessed across all major business segments. Vascular sales increased 8% year over year to $173.6 million. Growth was led by strong demand for the disposable electrophysiology (EP), biopsy, peripheral PTA catheters and stent products. This was partly offset by lower surgical graft product sales.

Urology sales increased 2% year over year to $177.5 million. Growth can be primarily attributed to strong sales of basic drainage and StatLock catheter stabilization products. However, this was partly mitigated by lower continence and IC Foley businesses.

Oncology sales increased 1% year over year to $171.6 million. Growth was led by higher sales of ports, PICC and Midline products. Surgical Specialties sales increased 3% year over year to $93.1 million.
-----
Looks like Bard is also seeing a decreasing in incontinence.
 






10 Warning Signs Your Company May Be In Trouble

Everyone who has ever worked knows there is no such thing as job security. And when times are uncertain as they are now, everyone’s anxiety level is higher. Unless you are at the very top of the corporate food chain, you probably don’t really know how well the company is doing. If the annual bonuses disappear or there are sudden cutbacks, does it mean your company is circling the drain?

The easiest way to identify the danger signs is to do your homework. Don’t rely on the internal rumor mill to keep you abreast of corporate events. Look outside the company and see what the rest of the world is saying. The business press often picks up on problems long before they become internal knowledge. Keep an eye on industry trends to see what the experts are forecasting. How is the company stock doing? Is there any recent news that could affect your company’s future? Here are 10 obvious things to watch for to see if your job might be in danger:

1.Merger rumors – If your company is looking to be acquired or merge, your job is in play, no matter what senior management says. Staff consolidation always follows a merger.
2.Poor profits – If you are having a bad year or there has been a major loss, then cutting positions is one way to cut costs. It all depends on where you are in the food chain.
3.New strategic hire – Is there a new sheriff in town? Or are consultants being brought on to address internal issues? It could be a harbinger of staff changes and job cuts.
4.External problems that affect the company – Has there been a watershed event, like new legislation or a big lawsuit or settlement? Remember, if there is a big call for cash or a change in your business climate, jobs are often the first to go.
•Failure to get certification or loss of a big contract – If you have a new product or strategy that relies on FDA approval or a government okay, then failure to get approval could mean downsizing. The same is true if you have one or two large customers who keep the doors open.
•Possible scandal – If your company makes a product that is linked to cancer or negative public opinion, then it could affect your future.
•Vendors aren’t being paid – If you start to hear complaints about delaying payment to suppliers, it could be a warning sign that money is tight.
•Budget cuts – If suddenly budgets have to be slashed, it means there’s a cash flow problem. Payroll could be next.
•Travel and training costs cut – When funding for business travel or education suddenly disappears, it could be a sign of financial stress.
•Early retirement – If the old-timers are being asked to retire early or agree to a voluntary separation program, it could be a signal there are financial problems.
Of course, every company and every situation is unique, but there are clear danger signals that anyone can read. Your best defense is a good offense. Start building your professional network now, so you will be prepared should the axe fall. You never know when you might need a friend to help you find your next job.

http://blog.netshare.com/2009/01/10-warning-signs-your-company-may-be-in-trouble.html
 






Anonymous said:
Study Type: Interventional
Study Design: Treatment, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Official Title: Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder


Further study details as provided by EMKinetics, Inc:


Primary Outcome Measures:
•Improved urinary frequency and urgency after 12 weeks of treatment. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]


Secondary Outcome Measures:
•To estimate the extent to which the device will decrease the number of episodes of involuntary urine loss due to frequency/urgency in comparison to historical controls [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

•To evaluate the potential of the device for improving patient quality of life as measured by a clinically validated scale, such as the Incontinence Quality of Life Instrument (I-QOL) or equivalent [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

•To periodically employ a micturition diary to record variables such as day/night urgency/frequency episodes, number of voids per day, severity of leaks, number of absorbent products used per day, etc [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]


Enrollment: 4
Study Start Date: December 2008
Estimated Study Completion Date: April 2010
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)

Intervention Details:
Device: MagPro R30
Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil.

The figure eight coil is placed directly over the posterior tibial nerve and the MagPro R30 will be activated.

The coil will stimulate the posterior tibial nerve at 20 pulses per second for a 30 minute session.

Detailed Description:
Twenty to Forty patients with documented overactive bladder will receive 30 minutes of treatment one day a week for 12 weeks. Treatment will consist of stimulating the posterior tibial nerve in the area of the ankle with a pulsed electromagnetic field. Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil, and a surface electrode placed over the afferent pathway of the sacral nerve.

The specific aim is improved urinary frequency and urgency after 12 weeks of treatment.

Secondary goals.

•To estimate the extent to which the device will decrease the number of episodes of involuntary urine loss due to frequency/urgency in comparison to historical controls.
•To evaluate the potential of the device for improving patient quality of life as measured by a clinically validated scale, such as the Incontinence Quality of Life Instrument (I-QOL) or equivalent
•To periodically employ a micturition diary to record variables such as day/night urgency/frequency episodes, number of voids per day, severity of leaks, number of absorbent products used per day, etc.
Eligibility


Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria
Inclusion Criteria:

•The patient is > 18 years old.
•The patient has ≥ 6 month history of documented overactive bladder.
•The patient has failed other conventional therapy (i.e.- Kegel exercises, biofeedback methodology, etc.).
•The patient is free of mechanical urethral obstruction as documented by cystoscopy or pressure flow criteria.
•The patient demonstrates an understanding of neuromodulation therapy, its benefits, and its potential risks.
•The patient is willing and able to keep accurate records of their voiding on the provided voiding diaries.
•The patient is willing and able to comply with the Study Protocol.
•The patient agrees to and is capable of answering a quality of life questionnaire.
•The patient has normal functioning of the upper urinary tract.
•The patient has an intact peripheral neurosensory system.
•If the patient is/was on pharmacologic treatment for urgency/frequency syndrome, a 10-day washout period prior to treatment must be completed.
•The patient has sufficient outlet resistance at the urinary sphincter (i.e.- the patient does not have intrinsic sphincter deficiency).
Exclusion Criteria:

•The patient is pregnant or intends to become pregnant during the course of the study. (Patients becoming pregnant during the course of the study will immediately be terminated from the study.) Warning: The effects of neuromodulation on a developing fetus are unknown
•The patient has an active urinary tract infection.
•The patient has abnormal cystoscopy, which is concerning for or indicative of malignancy.
•The patient has a urinary fistula.
•The patient has a bladder stone.
•The patient has had ankle injury or surgery which results inability to stimulate the tibial nerve or discomfort in using the foot cradle
•The patient has metal implant from surgery or a metallic foreign body in either leg below (distal to) the knee.
•The patient has cochlear implants.
•The patient has a hyperreflexic neurogenic bladder or urodynamically proven instability secondary to a known neurourologic cause (i.e.- stroke, Parkinson's, Multiple Sclerosis).
•The patient has had four or more urinary tract infections in the past year.
•The patient has a chronic disease or diminished mental capacity that, in the Principal Investigator's judgement, would impair their ability to successfully understand and comply with the protocol.
•The patient has a history of gross hematuria or glycosuria within the last year.
•The patient has chronic constipation (less than two (2) bowel movements per week).
•The patient has significant pathology that would compromise sphincter competency.
•The patient has uncontrolled diabetes.
•The patient has diagnosed peripheral neuropathy such as diabetes with peripheral nerve involvement.
•The patient has concomitant medical conditions that would limit the success of the procedure or confound study results, including but not limited to patients with nerve damage, pacemakers or implantable defibrillators.
•The patient is unable or unwilling to sign informed consent.
•The patient is on pharmacologic treatment that could affect bladder function.
•The patient has known moderate to severe ureteral reflux or hydronephrosis.
•The patient has severe urethral stricture(s).
Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00805779

Locations
United States, California
UCSF Urology Faculty Practice
San Francisco, California, United States, 94122
Sponsors and Collaborators
EMKinetics, Inc
Investigators
Principal Investigator: Donna Y Deng, MD UCSF Department of Urology

More Information

No publications provided

Responsible Party: UCSF ( Donna Deng, MD/Assistant Professor )
Study ID Numbers: EMK1208
Study First Received: December 8, 2008
Last Updated: June 2, 2009
ClinicalTrials.gov Identifier: NCT00805779 History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by EMKinetics, Inc:
Overactive Bladder
Overactive Urinary Bladder
Bladder, Overactive
Overactive Detrusor
Detrusor, Overactive
Overactive Detrusor Function
Detrusor Function, Overactive



Study placed in the following topic categories:
Signs and Symptoms
Urinary Bladder, Overactive
Cystocele
Urologic Diseases
Urinary Bladder Diseases



Additional relevant MeSH terms:
Signs and Symptoms
Urological Manifestations
Urinary Bladder, Overactive
Urologic Diseases
Urinary Bladder Diseases



ClinicalTrials.gov processed this record on September 04, 2009
Click to expand...

I bet they will have a code BEFORE involving their clients.
 






Since its founding in 1994, CCS Medical has been dedicated to making it easy and affordable for patients to receive their medical supplies. CCS Medical's uncompromising commitment to providing reliable home delivery of quality products, superior customer care and single source convenience has established a solid reputation among patients, healthcare professionals and industry leading manufacturers such as: Roche (Accu-Chek), Bayer Diagnostics (Ascensia), Johnson & Johnson (Lifescan), Abbott, and Medtronic (MiniMed).

Recognized as one of the most recommended providers nationwide, CCS Medical offers a broad variety of services and the convenient home delivery of:

Diabetes Testing Supplies
Insulin Pumps and Pump Supplies
Prescription Medication
Nebulizer Supplies and Medications
Ostomy Supplies
Urological Supplies
Wound Care Supplies
Incontinence Supplies
CCS Medical's comprehensive program encourages adherence to prescribed self-management regimes and gives patients access to Certified Diabetes Educators, Respiratory Therapists and Pharmacists.

CCS Medical is a participating Medicare provider, accepting Medicaid in most states, as well as most private and major medical insurance plans. Claims are processed on behalf of patients to help minimize up-front and out-of-pocket expenses. Knowledgeable Reimbursement Representatives assist patients with Medicare and insurance requirements and the processing of paperwork to ensure patients receive their full benefits.

The specialized focus of working with physicians, educators and other healthcare professionals sets CCS Medical apart within the industry. Moving forward, CCS Medical will continue to enhance patient satisfaction and remain focused on offering only the highest quality products and services.

position description
Medical Device Sales- Urology Minneapolis, MN

The Account Executive is accountable for selling, promoting, and delivering a portfolio of urological and incontinent products and service accounts in targeted market segments, and contributing to CCS Medical sales and profit goals. The Account Executive operates with general supervision within an assigned geographic territory. The territory consists of the entire state of Minnesota.

ESSENTIAL DUTIES AND RESPONSIBILITIES


· Maintains and grows business within an assigned territory by developing an effective planning process (a business plan) and maintaining complete records of all high volume accounts, which include focused self-test markets and top-decile healthcare providers

· Acts to meet/exceed customer expectations by sustaining regular contact and building superior relationships with key healthcare decision-makers and influencers

· Promotes customer brand loyalty by participating in or joining regional or local urological professional organizations that serve health care providers and or consumers

· Demonstrates competency in the company’s products and services by managing the entire sales process, presenting (oral and written) all aspects of the company products, maintaining working knowledge of existing marketing programs

· Builds CCS Medical image as a leader in providing medical supplies by engaging in promotional activities and by attending conventions, meetings, and symposiums, as assigned or directed

· Practices expense control by keeping within a defined budget and managing given resources

· Competently communicates on a daily basis using all mediums available – phone-mail, e-mail, etc. in order to adequately report data on the industry, territory, market trends, promotion and competitive activity

· Primary sales focus involves gaining the recommendation of medical providers (e.g. Physicians, Nurses, third-party payer personnel, etc.); a secondary emphasis is assuring patient or consumer access to the product or services through the services of CCS Medical; a third responsibility is to work closely with all manufacturer sales reps to develop key targets and build customer base

· Maintains and inputs sales territory records and to complete sales data and promotional information

OTHER RESPONSIBILITIES

· Must be self-motivated, organized, personable, and possess excellent communication skills to prioritize activities with targeted high volume accounts and to interact with manufacturer reps and management.

· Must be current in their knowledge of all products, services, and marketing programs within CCS Medical

· Must maintain a working knowledge of urology health care market, industry/customer buying processes, competitive product and selling information

· Required to develop/possess the ability to prioritize sales activities needed to best drive the business in their geographic territory

· Maintains and promotes patient confidentiality

· Maintains open lines of communication with Administration, department management and other departmental personnel

· Follows all Medicare, Medicaid and Private Insurance regulations and requirements

· Actively participates in Continuous Quality Improvement

· Demonstrates thoroughness with all work related activities. Strives to continually improve quality and productivity results displayed by Department Personnel on an ongoing basis

· Assumes other duties and responsibilities as assigned by manager

· Maintains scheduling flexibility to ensure availability to meet the needs of the department for all hours of operation and maintains regular and consistent attendance

· Abides by all policies, procedures and protocols set forth in the departmental, CCS Medical Personnel and Administrative Policy Manuals.

· Is compliant with all CCS Medical safety policies and protocols, completes all necessary safety training, and obeys all traffic rules and signs.



Note: The above statements describe the general nature and level of the work being performed and are not an exhaustive list of all responsibilities of an employee in this job. Job duties can change at any time as directed by management. Furthermore, they do not establish a contract for employment and are subject to change at the discretion of the employer.

POSITION ACCOUNTABILITY

Budgets: Works within an annualized budget, maintaining accurate expense records

Profits: Directly affected by the business growth plan and retention current membership and future membership and revenue, as developed and directed by the CEO

Cost Control: Ensures effective documentation and adherence to Medicare and Private insurance guidelines to facilitate proper payment and reduce waste

Quality Control: Ensures that company philosophies, policies, and procedures regarding patients, government agencies, and other vendors are maintained

Confidentiality: Adheres to HIPAA guidelines, company privacy and confidentiality policies

Customer Service: Ensures that client relations are treated with the highest level of customer service, per company policies

Compliance: Ensures effective documentation and adherence to Medicare and Private insurance guidelines

Records: Responsible for maintaining accurate patient records

RESPONSIBILITY

Reports to: Department Manager

Supervisory: None

PRIMARY CUSTOMERS

Internal: Department Managers, Business Development employees

External: Health Care Medical Provider, Physicians (Primary Care, Internist, Endocrinologist and Diabetologist), Physician Assistants, Nursing personnel (office, private industry, managed care, hospital setting), Nurse Specialty groups (Diabetes educators, Nurse Practitioners), Registered Dieticians, diagnostics manufacturers



KNOWLEDGE SKILLS AND ABILITIES REQUIRED



· Bachelor’s Degree (BA) from a four-year college or university and three years of Sales experience or the equivalent combination of education and/or experience. Two or more years of outside sales experience is preferred.

· Ability to read, analyze and interpret general business periodicals, professional journals, technical procedures or government regulations; ability to write reports, business correspondence, and procedure manuals; ability to effectively present information and respond to questions from groups of managers, clients, customers and the general public

· Excellent communication and interpersonal skills are required when dealing with customers, fellow employees, and management



DESIRED KEY COMPETENCIES



· Must be organized, self-motivated, and possess basic business knowledge (e.g. sales, marketing, finance) to meet/exceed sales objectives

· Quick learner to address customer questions or objectives based on technical knowledge of the product or disease state

· Proficient with various Microsoft Office software such as Word, Excel and PowerPoint

· Strong planning, organization and execution skills

· Strong impact and influence

· Strong interpersonal skills

· Resource Allocation

· Information Management

· Facilitation/Presentation Skills

· Learning Orientation

· Judgement and Decision Making

· Teamwork and Team Leadership



Employees enjoy great health, dental, and disability insurance benefits (large portion of premiums paid by the company), including a 401K plan with company match and vesting schedule, plus paid time off within the first year. EEO/DFWP.

If your experience meets the requirements listed above, and you would like to be considered for this position, please forward your resume to CCS Medical at salesjobs@ccsmed.com .
 






Medical Device Sales- Urology- Columbus, Ohio

The Account Executive is acccountable for selling, promoting, and delivering a portfolio of urological and incontinent products and services in targeted markets segments, and contributing to CCS Medical sales and profit goals. The Account Executive operates with general supervision within an assigned geographic territory. This territory consists of the entire state of Ohio.

ESSENTIAL DUTIES AND RESPONSIBILITIES


· Maintains and grows business within an assigned territory by developing an effective planning process (a business plan) and maintaining complete records of all high volume accounts, which include focused self-test markets and top-decile healthcare providers

· Acts to meet/exceed customer expectations by sustaining regular contact and building superior relationships with key healthcare decision-makers and influencers

· Promotes customer brand loyalty by participating in or joining regional or local Urological professional organizations that serve health care providers and or consumers

· Demonstrates competency in the company’s products and services by managing the entire sales process, presenting (oral and written) all aspects of the company products, maintaining working knowledge of existing marketing programs

· Builds CCS Medical image as a leader in providing medical supplies by engaging in promotional activities and by attending conventions, meetings, and symposiums, as assigned or directed

· Practices expense control by keeping within a defined budget and managing given resources

· Competently communicates on a daily basis using all mediums available – phone-mail, e-mail, etc. in order to adequately report data on the industry, territory, market trends, promotion and competitive activity

· Primary sales focus involves gaining the recommendation of medical providers (e.g. Physicians, Nurses, third-party payer personnel, etc.); a secondary emphasis is assuring patient or consumer access to the product or services through the services of CCS Medical; a third responsibility is to work closely with all manufacturer sales reps to develop key targets and build customer base

· Maintains and inputs sales territory records and to complete sales data and promotional information



OTHER RESPONSIBILITIES



· Must be self-motivated, organized, personable, and possess excellent communication skills to prioritize activities with targeted high volume accounts and to interact with manufacturer reps and management.

· Must be current in their knowledge of all products, services, and marketing programs within CCS Medical

· Must maintain a working knowledge of Urological health care market, industry/customer buying processes, competitive product and selling information

· Required to develop/possess the ability to prioritize sales activities needed to best drive the business in their geographic territory

· Maintains and promotes patient confidentiality

· Maintains open lines of communication with Administration, department management and other departmental personnel

· Follows all Medicare, Medicaid and Private Insurance regulations and requirements

· Actively participates in Continuous Quality Improvement

· Demonstrates thoroughness with all work related activities. Strives to continually improve quality and productivity results displayed by Department Personnel on an ongoing basis

· Assumes other duties and responsibilities as assigned by manager

· Maintains scheduling flexibility to ensure availability to meet the needs of the department for all hours of operation and maintains regular and consistent attendance

· Abides by all policies, procedures and protocols set forth in the departmental, CCS Medical Personnel and Administrative Policy Manuals.

· Is compliant with all CCS Medical safety policies and protocols, completes all necessary safety training, and obeys all traffic rules and signs.



Note: The above statements describe the general nature and level of the work being performed and are not an exhaustive list of all responsibilities of an employee in this job. Job duties can change at any time as directed by management. Furthermore, they do not establish a contract for employment and are subject to change at the discretion of the employer.



POSITION ACCOUNTABILITY



Budgets: Works within an annualized budget, maintaining accurate expense records

Profits: Directly affected by the business growth plan and retention current membership and future membership and revenue, as developed and directed by the CEO

Cost Control: Ensures effective documentation and adherence to Medicare and Private insurance guidelines to facilitate proper payment and reduce waste

Quality Control: Ensures that company philosophies, policies, and procedures regarding patients, government agencies, and other vendors are maintained

Confidentiality: Adheres to HIPAA guidelines, company privacy and confidentiality policies

Customer Service: Ensures that client relations are treated with the highest level of customer service, per company policies

Compliance: Ensures effective documentation and adherence to Medicare and Private insurance guidelines

Records: Responsible for maintaining accurate patient records



RESPONSIBILITY


Reports to: Department Manager

Supervisory: None



PRIMARY CUSTOMERS


Internal: Department Managers, Business Development employees

External: Health Care Medical Provider, Physicians (Primary Care, Internist, Endocrinologist and Diabetologist), Physician Assistants, Nursing personnel (office, private industry, managed care, hospital setting), Nurse Specialty groups (Diabetes educators, Nurse Practitioners), Registered Dieticians, diagnostics manufacturers



KNOWLEDGE SKILLS AND ABILITIES REQUIRED



· Bachelor’s Degree (BA) from a four-year college or university and three years of Sales experience or the equivalent combination of education and/or experience. Two or more years of outside sales experience is preferred.

· Ability to read, analyze and interpret general business periodicals, professional journals, technical procedures or government regulations; ability to write reports, business correspondence, and procedure manuals; ability to effectively present information and respond to questions from groups of managers, clients, customers and the general public

· Excellent communication and interpersonal skills are required when dealing with customers, fellow employees, and management



DESIRED KEY COMPETENCIES



· Must be organized, self-motivated, and possess basic business knowledge (e.g. sales, marketing, finance) to meet/exceed sales objectives

· Quick learner to address customer questions or objectives based on technical knowledge of the product or disease state

· Proficient with various Microsoft Office software such as Word, Excel and PowerPoint

· Strong planning, organization and execution skills

· Strong impact and influence

· Strong interpersonal skills

· Resource Allocation

· Information Management

· Facilitation/Presentation Skills

· Learning Orientation

· Judgement and Decision Making

· Teamwork and Team Leadership





Employees enjoy great health, dental, and disability insurance benefits (large portion of premiums paid by the company), including a 401K plan with company match and vesting schedule, plus paid time off within the first year. EEO/DFWP.

If your experience meets the requirements listed above, and you would like to be considered for this position, please forward your resume to CCS Medical at salesjobs@ccsmed.com .



Send this job to a friend See all CCS Medical opportunities
 






Medical Device Sales- Urology Houston, Texas



The Account Executive is accountable for selling, promoting, and delivering a portfolio of urological and incontinent products and service accounts in targeted market segments, and contributing to CCS Medical sales and profit goals. The Account Executive operates with general supervision within an assigned geographical territory. The territory consists of Houston, San Antonio, and surrounding territory.



ESSENTIAL DUTIES AND RESPONSIBILITIES


· Maintains and grows business within an assigned territory by developing an effective planning process (a business plan) and maintaining complete records of all high volume accounts, which include focused self-test markets and top-decile healthcare providers

· Acts to meet/exceed customer expectations by sustaining regular contact and building superior relationships with key healthcare decision-makers and influencers

· Promotes customer brand loyalty by participating in or joining regional or local urological professional organizations that serve health care providers and or consumers

· Demonstrates competency in the company’s products and services by managing the entire sales process, presenting (oral and written) all aspects of the company products, maintaining working knowledge of existing marketing programs

· Builds CCS Medical image as a leader in providing medical supplies by engaging in promotional activities and by attending conventions, meetings, and symposiums, as assigned or directed

· Practices expense control by keeping within a defined budget and managing given resources

· Competently communicates on a daily basis using all mediums available – phone-mail, e-mail, etc. in order to adequately report data on the industry, territory, market trends, promotion and competitive activity

· Primary sales focus involves gaining the recommendation of medical providers (e.g. Physicians, Nurses, third-party payer personnel, etc.); a secondary emphasis is assuring patient or consumer access to the product or services through the services of CCS Medical; a third responsibility is to work closely with all manufacturer sales reps to develop key targets and build customer base

· Maintains and inputs sales territory records and to complete sales data and promotional information



OTHER RESPONSIBILITIES



· Must be self-motivated, organized, personable, and possess excellent communication skills to prioritize activities with targeted high volume accounts and to interact with manufacturer reps and management.

· Must be current in their knowledge of all products, services, and marketing programs within CCS Medical

· Must maintain a working knowledge of urological health care market, industry/customer buying processes, competitive product and selling information

· Required to develop/possess the ability to prioritize sales activities needed to best drive the business in their geographic territory

· Maintains and promotes patient confidentiality

· Maintains open lines of communication with Administration, department management and other departmental personnel

· Follows all Medicare, Medicaid and Private Insurance regulations and requirements

· Actively participates in Continuous Quality Improvement

· Demonstrates thoroughness with all work related activities. Strives to continually improve quality and productivity results displayed by Department Personnel on an ongoing basis

· Assumes other duties and responsibilities as assigned by manager

· Maintains scheduling flexibility to ensure availability to meet the needs of the department for all hours of operation and maintains regular and consistent attendance

· Abides by all policies, procedures and protocols set forth in the departmental, CCS Medical Personnel and Administrative Policy Manuals.

· Is compliant with all CCS Medical safety policies and protocols, completes all necessary safety training, and obeys all traffic rules and signs.



Note: The above statements describe the general nature and level of the work being performed and are not an exhaustive list of all responsibilities of an employee in this job. Job duties can change at any time as directed by management. Furthermore, they do not establish a contract for employment and are subject to change at the discretion of the employer.



POSITION ACCOUNTABILITY



Budgets: Works within an annualized budget, maintaining accurate expense records

Profits: Directly affected by the business growth plan and retention current membership and future membership and revenue, as developed and directed by the CEO

Cost Control: Ensures effective documentation and adherence to Medicare and Private insurance guidelines to facilitate proper payment and reduce waste

Quality Control: Ensures that company philosophies, policies, and procedures regarding patients, government agencies, and other vendors are maintained

Confidentiality: Adheres to HIPAA guidelines, company privacy and confidentiality policies

Customer Service: Ensures that client relations are treated with the highest level of customer service, per company policies

Compliance: Ensures effective documentation and adherence to Medicare and Private insurance guidelines

Records: Responsible for maintaining accurate patient records



RESPONSIBILITY


Reports to: Department Manager

Supervisory: None



PRIMARY CUSTOMERS


Internal: Department Managers, Business Development employees

External: Health Care Medical Provider, Physicians (Primary Care, Internist, Endocrinologist and Diabetologist), Physician Assistants, Nursing personnel (office, private industry, managed care, hospital setting), Nurse Specialty groups (Diabetes educators, Nurse Practitioners), Registered Dieticians, diagnostics manufacturers



KNOWLEDGE SKILLS AND ABILITIES REQUIRED



· Bachelor’s Degree (BA) from a four-year college or university and three years of Sales experience or the equivalent combination of education and/or experience. Two or more years of outside sales experience is preferred.

· Ability to read, analyze and interpret general business periodicals, professional journals, technical procedures or government regulations; ability to write reports, business correspondence, and procedure manuals; ability to effectively present information and respond to questions from groups of managers, clients, customers and the general public

· Excellent communication and interpersonal skills are required when dealing with customers, fellow employees, and management



DESIRED KEY COMPETENCIES



· Must be organized, self-motivated, and possess basic business knowledge (e.g. sales, marketing, finance) to meet/exceed sales objectives

· Quick learner to address customer questions or objectives based on technical knowledge of the product or disease state

· Proficient with various Microsoft Office software such as Word, Excel and PowerPoint

· Strong planning, organization and execution skills

· Strong impact and influence

· Strong interpersonal skills

· Resource Allocation

· Information Management

· Facilitation/Presentation Skills

· Learning Orientation

· Judgement and Decision Making

· Teamwork and Team Leadership







Employees enjoy great health, dental, and disability insurance benefits (large portion of premiums paid by the company), including a 401K plan with company match and vesting schedule, plus paid time off within the first year. EEO/DFWP.

If your experience meets the requirements listed above, and you would like to be considered for this position, please forward your resume to CCS Medical at salesjobs@ccsmed.com .
 






Top Bottom
Back
Quote